| [1] | Gao XiaoHong, Cheng Ni, Cao JiaoJiao. Clinical cure in patients with hepatitis B cirrhosis treated with pegylated interferon α-2b: A case report[J]. Journal of Clinical Hepatology, 2020, 36(6): 1347-1348. doi: 10.3969/j.issn.1001-5256.2020.06.031 |
| [2] | Chen Xi, Zhao WenJing, Sun Yan, Yin HaiYan. Value of baseline HBsAg quantification in predicting the clinical effect of pegylated interferon α-2b in treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2020, 36(8): 1723-1726. doi: 10.3969/j.issn.1001-5256.2020.08.009 |
| [3] | Ji WeiJia, Yan XueBing. Clinical effect and safety of pegylated interferon-α-2a versus pegylated interferon-α-2b in treatment of chronic hepatitis B [J]. Journal of Clinical Hepatology, 2019, 35(2): 309-314. doi: 10.3969/j.issn.1001-5256.2019.02.013 |
| [4] | Wan MoBin. Individualized treatment with pegylated interferon-α for chronic hepatitis B[J]. Journal of Clinical Hepatology, 2018, 34(5): 930-933. doi: 10.3969/j.issn.1001-5256.2018.05.004 |
| [5] | Lou Xin, Gao YuFeng, Ye Jun, Wang YinQiu, Guan ZiShu, Zou GuiZhou. Clinical effect of pegylated interferon α-2a in treatment of previously untreated HBeAg-positive chronic hepatitis B patients and related predictive factors[J]. Journal of Clinical Hepatology, 2018, 34(5): 995-1000. doi: 10.3969/j.issn.1001-5256.2018.05.014 |
| [6] | You Jia, Chen Jing, Ye QiaoXia, Zheng Qi, Zhu YueYong, Dong Jing, Liu YuRui, Jiang JiaJi. Efficacy of add- on adefovir dipivoxil at week 12 /24 in HBe Ag- positive chronic hepatitis B patients during PEG-IFNα therapy[J]. Journal of Clinical Hepatology, 2016, 32(4): 687-690. doi: 10.3969/j.issn.1001-5256.2016.04.015 |
| [7] | Li Yan, Wang Xia, Cheng LiWei, Pan XiuCheng, Dan Ben, Geng Jian, Liu RuiXia, Fu JuanJuan, Li Li. Effects of serum levels of chemokines on sustained virological response in patients with HBeAg-positive chronic hep-atitis B after treatment with pegylated interferon α-2b[J]. Journal of Clinical Hepatology, 2016, 32(3): 467-471. doi: 10.3969/j.issn.1001-5256.2016.03.013 |
| [8] | Yang Long, Yang Yang, Jiang XueHua, Chen ZhiYong. Efficacy of peginterferon α- 2a in treatment of chronic hepatitis B resistant to multiple nucleos( t) ide analogues[J]. Journal of Clinical Hepatology, 2016, 32(4): 691-694. doi: 10.3969/j.issn.1001-5256.2016.04.016 |
| [9] | Peng MeiJuan, Wang Wei, Yang XiaoFei, Hao ChunQiu, Bai XueFan, Jia ZhanSheng, Lian JianQi, Zhang Ye. Influence of pegylated interferonα- 2a versus telbivudine on renal function in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(4): 682-686. doi: 10.3969/j.issn.1001-5256.2016.04.014 |
| [10] | Gao AiHua, Zhang YuGuo, Nan YueMin. Research advances in predictors of treatment responses to pegylated interferon alpha in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2015, 31(4): 594-598. doi: 10.3969/j.issn.1001-5256.2015.04.029 |
| [11] | Liu YunHua, Li Zhen, Liu Li, Peng Dan, Li WeiKun, Chang LiXian, Jia Ting, Yang YongRui, Li HuiMin, Wang LiQian. Clinical study of pegylated interferon α-2a in treatment of children with HBe Ag-positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2015, 31(2): 193-197. doi: 10.3969/j.issn.1001-5256.2015.02.012 |
| [12] | Liu ZhiHua, He HaiTang, Hu Jing, Fu QunXiang, Luo KangXian. Efficacy of pegylated interferon α-2a in HBe Ag-negative chronic hepatitis B patients and its influencing factors[J]. Journal of Clinical Hepatology, 2015, 31(5): 697-701. doi: 10.3969/j.issn.1001-5256.2015.05.016 |
| [13] | Lu JianGuo. Effect of pegylated interferon α-2a combined with thymosin α1 on quality of life in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2013, 29(12): 922-925. doi: 10.3969/j.issn.1001-5256.2013.12.012 |
| [14] | Wei Xin, Xie YuMei, Chen Lin, Pan Lei, Hao ChunQiu, Wang JiuPing, Bai XueFan, Jia ZhanSheng. Antiviral therapy with pegylated interferon alpha-2a plus ribavirin in patients with HCV related cirrhosis and to establish the grading for standard therapy[J]. Journal of Clinical Hepatology, 2011, 27(1): 89-92. |
| [15] | Zhu HaiJuan, Li YongHong, Guo LiPing. One case report of hysteria in a HCV patient being treated with PEG-IFN α-2a[J]. Journal of Clinical Hepatology, 2011, 27(6): 656-657. |
| [16] | Zheng YingYing, Fan XiaoHong, Wang LiFen, Tian Di, Huo Na, Lu HaiYing, Wu ChiHong, Xu XiaoYuan, Wei Lai. Efficacy and side effects of PEG-IFNα-2a plus ribavirin on elderly patients with chronic hepatitis C[J]. Journal of Clinical Hepatology, 2011, 27(8): 821-823. |
| [17] | Jiang XueQiang, Zou XiaoJing, Tian DeYing. Virological response of chronic hepatitis C treated with peg-interferon α-2a and Ribavirin[J]. Journal of Clinical Hepatology, 2011, 27(4): 417-419. |
| [18] | Pan Lei, Wei Xin, Xie YuMei, Hao ChunQiu, Wang JiuPing, Jia ZhanSheng, Bai XueFan. Anti-viral therapy with pegylated interferon alpha-2a plus ribavirin in patients co-infected with HBV and HCV[J]. Journal of Clinical Hepatology, 2011, 27(1): 84-85+95. |
| [19] | Zhao Ping, Wang JiangBin, Jiao Jian. Response to PEG-IFN α-2a by chronic hepatitis C patients with autoimmune features[J]. Journal of Clinical Hepatology, 2010, 26(4): 374-376. |
DownLoad: